<p>BOAN BIOTECH Hong Kong Stock Exchange announcement, the company's independently developed Boyouping® (Dulaglutide Injection) has received marketing approval from the National Medical Products Administration for blood glucose control in adult patients with type 2 diabetes. Boyouping® is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist, and its commercialization in mainland China is carried out in collaboration with Shanghai Pharmaceuticals Holding</p>

06955

<p>BOAN BIOTECH's independently developed Boyouping® (Dulaglutide Injection) has received marketing approval from the National Medical Products Administration, primarily for blood sugar control in adult patients with type 2 diabetes. This drug is a long-acting GLP-1 receptor agonist, and its commercialization is carried out in collaboration with Shanghai Pharmaceuticals Holding</p>

博安生物自主开发药物度拉糖肽注射液获批上市